Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Federal Trade Commission
Cantor Fitzgerald
McKinsey
McKesson
Teva
Colorcon
Farmers Insurance
Accenture

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,977,257

« Back to Dashboard

Which drugs does patent 6,977,257 protect, and when does it expire?

Patent 6,977,257 protects ABILIFY and is included in one NDA.

Protection for ABILIFY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-eight patent family members in thirty-seven countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.
Summary for Patent: 6,977,257
Title: Aripiprazole oral solution
Abstract:The present invention provides for a pharmaceutical solution suitable for oral administration comprising aripiprazole, a pharmaceutically suitable solvent system, one or more taste-enhancing/masking agents and one or more agents selected from the group consisting of lactic acid, acetic acid, tartaric acid and citric acid, wherein said solution has a pH from 2.5 to 4.5.
Inventor(s): Parab; Prakash V. (Monroe Township, NJ), Chou; Joyc Tianw i (Fremont, CA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/131,304
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,977,257
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Drugs Protected by US Patent 6,977,257

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka ABILIFY aripiprazole SOLUTION;ORAL 021713-001 Dec 10, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,977,257

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2003132426 ➤ Try a Free Trial
Serbia 52082 ➤ Try a Free Trial
Yugoslavia 84703 ➤ Try a Free Trial
Portugal 1381367 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Citi
Cerilliant
Julphar
Harvard Business School
Fuji
Fish and Richardson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.